SRIT India Limited plans Rs 5 crore Carnot investment, path to 20%

SRIT India Limited plans to invest Rs 5 crore in Carnot Research Private Limited for a 10.00% fully diluted stake, subject to conditions and definitive agreements. SRIT India’s July 31, 2026 term sheet also contemplates a later primary investment that could raise its holding to 20.00% within 12 to 18 months after completion.

What is SRIT India’s proposed Carnot investment?

SRIT India has agreed in principle to invest Rs 5 crore in Carnot for 10.00% of its issued and paid-up equity capital on a fully diluted basis, subject to completion conditions. The July 31, 2026 term sheet gives Carnot an indicative equity valuation of Rs 50 crore on a debt-free and cash-free basis and specifies an issue price of Rs 2,000 per equity share, comprising Rs 10 face value and Rs 1,990 securities premium. The investment amount is to be disbursed within no more than 90 calendar days after conditions in the definitive agreements are fulfilled.

The contemplated post-completion capital structure contains 2,50,000 equity shares of Rs 10 each. SRIT India would hold 25,000 shares, or 10.00%; Dr. Amit Oberoi would hold 1,23,750 shares, or 49.50%; Dr. Birejsh Lall would hold 98,750 shares, or 39.50%; and FITT, IIT Delhi would hold 2,500 shares, or 1.00%. The two founders would retain a combined 89.00% after completion, making SRIT India’s proposed holding a minority interest rather than control.

How could SRIT India increase its Carnot investment to 20%?

SRIT India’s path from 10.00% to 20.00% is a contemplated future primary equity investment, not an automatic completed acquisition. Under the July 31, 2026 term sheet, SRIT India may make that investment within 12 months, and no later than 18 months, from completion of the initial transaction. The valuation for the second investment is not fixed at the Rs 50 crore indicative valuation stated for the initial proposal; it is to be determined by an independent valuer mutually appointed by the parties.

The initial transaction remains conditional on legal, financial, tax, technical and commercial due diligence by SRIT India with results satisfactory to it. It also requires execution of a shareholders’ agreement, a share subscription agreement and other definitive documents, as well as fulfilment of other conditions precedent. The August 18, 2026 supplemental term sheet extended the period for executing definitive agreements from 30 days to 120 days from July 31, 2026, unless the parties agree a further written extension.

The transaction disclosure also states that valuation for the investment amount will be determined by a mutually appointed independent valuer of repute upon execution of the definitive agreements. This differs from the term sheet’s Rs 50 crore indicative equity valuation and means the disclosure does not report a final transaction valuation. Neither the initial 10.00% holding nor the later 20.00% outcome is reported as completed.

What operational support and investor rights would SRIT India receive?

SRIT India’s June 13, 2026 strategic incubation and investor protection agreement provides a framework for Carnot’s growth, development, commercialisation and scaling. Under that agreement, SRIT India may provide office infrastructure, technical resources, laboratories, mentoring, customer introductions, investor-network access, legal and compliance guidance, marketing support, recruitment support and other business-development opportunities. These are potential services under the framework rather than disclosed committed spending in addition to the proposed Rs 5 crore equity investment.

The incubation agreement also gives SRIT India access to information about Carnot’s progress, performance and financial health, a preferential right to participate in future investment opportunities, and tag-along rights in specified circumstances. A preferential participation right allows an investor to participate in subsequent investment opportunities, while a tag-along right allows it to join a specified shareholder sale on the applicable terms. The agreement and term sheet also address confidentiality, intellectual property, non-solicitation, non-circumvention, representations and warranties, indemnification, termination, limitation of liability and dispute resolution.

The operational framework is paired with the 10.00% proposed shareholding rather than a stated management-control right. The term sheet does not state that SRIT India would appoint a majority of Carnot’s board or that Carnot would become a subsidiary. The proposed relationship would therefore depend on completion of the transaction, the definitive agreements and the use of the contractual information, participation and tag-along rights described in the June 13, 2026 agreement.

How does Dr. Amit Oberoi’s SRIT India board role affect the transaction?

Dr. Amit Oberoi is disclosed as a Carnot co-founder, chief executive officer and director, and became a non-executive director of SRIT India on August 10, 2026. The Carnot term sheet was dated July 31, 2026, after the June 13, 2026 incubation agreement but before Dr. Oberoi’s SRIT India board appointment. The transaction disclosure identifies Dr. Oberoi and Dr. Birejsh Lall as the proposed selling shareholders.

The acquisition table separately records the relationship of SRIT India’s promoters or directors with the persons from whom it proposes to acquire as “Nil.” As of the red herring prospectus date, SRIT India had 10 directors: one managing director and chief executive officer, two whole-time directors, four independent directors and three non-executive directors. Dr. Oberoi’s disclosed directorship at Carnot and board position at SRIT India make the completion conditions and definitive agreements material to the proposed transaction’s structure.

Dr. Oberoi’s August 10, 2026 appointment letter provides for a sitting fee of Rs 30,000 for each SRIT India board meeting and Rs 15,000 for each committee meeting. He received no remuneration or sitting fees in Fiscal 2026 because the disclosure says he was appointed in Fiscal 2027. The source does not disclose any completed transfer of Carnot shares to SRIT India as a result of his board appointment.

How does the Carnot proposal compare with SRIT India’s subsidiaries?

Carnot is proposed as a 10.00% minority investment, while SRIT India’s disclosed subsidiaries are controlled entities. RICT India Private Limited is 94.00% owned by SRIT India, Sharp and Turner LLP is 99.92% held by SRIT India, and SRIT Life Sciences LLP is 51.00% held by SRIT India. SRIT India disclosed no associates or joint ventures as of the red herring prospectus date.

The 10.00% fully diluted Carnot holding would not make Carnot a subsidiary under the stated post-completion shareholding pattern. Even if SRIT India later reaches 20.00%, the source does not state that it would obtain control, board-majority rights or subsidiary status. In contrast, SRIT India became a 99.92% partner of Sharp and Turner LLP under a March 17, 2025 amendment deed, after which the LLP became its subsidiary.

The comparison shows that Carnot’s proposed connection to SRIT India would rest on minority ownership, contractual incubation and investor protections rather than on disclosed voting control. Its continuation depends first on satisfactory due diligence and definitive agreements, then on whether SRIT India pursues the separately contemplated primary investment. The 20.00% target is therefore a possible later ownership level, not a disclosed completed group-structure change.

Conclusion

SRIT India’s proposed Carnot investment combines a Rs 5 crore minority equity transaction with a structured operating-support arrangement and contractual investor protections. The initial 10.00% stake would leave the founders with 89.00% collectively, while a later primary investment could raise SRIT India’s holding to 20.00% without any stated transfer of control.

The next disclosed milestone is execution of definitive agreements within 120 days of July 31, 2026, unless the parties mutually agree a written extension, following SRIT India’s satisfactory due diligence. Any later investment designed to take SRIT India from 10.00% to 20.00% would require a valuation determined by an independent valuer mutually appointed by the parties.